Asston Pharmaceuticals Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 10039662,
    "name": "Asston Pharmaceu",
    "stock_name": "Asston Pharmaceu",
    "full_name": "Asston Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/asston-pharmaceu",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "80.00",
    "chg": -4,
    "chgp": "-4.76%",
    "dir": -1,
    "prev_price": "84.00",
    "mcapval": "74.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 544445,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE0SJX01015",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": 18000,
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/asston-pharmaceu-10039662-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Asston Pharmaceu overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-asston-pharmaceu-overvalued-or-undervalued-3732804",
        "imagepath": "",
        "date": "2025-11-27 08:53:32",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Valuation Metrics and Financial Performance</strong></p>\n<p>Asston Pharmaceu’s price-to-earnings (PE) ratio of 22.11 places it in the expensive category relative to its historical valuation grade, which recently changed from fair to expensive as of 26 November 2025. The price-to-book value stands at 2.20, indicating the market values the company at more than twice its net asset value. Its enterprise value to EBIT and EBITDA ratios, at 16.47 and 16.35 respectively, suggest the stock is priced at a premium compared to the earnings before interest and taxes and depreciation.</p>\n<p>The company’s return on capital employed (ROCE) is 12.72%, while return on equity (ROE) is 9.97%. These figures demonstrate moderate efficiency in generating returns from capital and equity, but they do not markedly ..."
      },
      {
        "title": "Is Asston Pharmaceu overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-asston-pharmaceu-overvalued-or-undervalued-3710274",
        "imagepath": "",
        "date": "2025-11-18 08:30:42",
        "description": "As of 17 November 2025, the valuation grade for Asston Pharmaceu has moved from very expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE Ratio of 18.10, an EV to EBIT of 13.61, and a ROCE of 12.72%. \n\nIn comparison to its peers, Asston Pharmaceu's PE Ratio is significantly lower than that of Sun Pharma, which stands at 36.69, and Divi's Lab, which has a PE of 69.78, both of which are categorized as expensive. Conversely, it is on par with Aurobindo Pharma, which is also considered fair with a PE of 21.23. Notably, Asston Pharmaceu has outperformed the Sensex over the past week, returning 6.16% compared to the Sensex's 1.69%...."
      },
      {
        "title": "How has been the historical performance of Asston Pharmaceu?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-asston-pharmaceu-3704451",
        "imagepath": "",
        "date": "2025-11-15 00:39:57",
        "description": "Answer:\nThe historical performance of Asston Pharmaceu shows significant growth in various financial metrics from March 2024 to March 2025.\n\nBreakdown:\nAsston Pharmaceu reported net sales of 25.04 Cr in March 2025, a notable increase from 15.59 Cr in March 2024. Total operating income also rose to 25.04 Cr from 15.59 Cr, driven by an increase in raw material costs to 14.13 Cr from 9.75 Cr. The total expenditure, excluding depreciation, increased to 18.87 Cr from 13.04 Cr, resulting in an operating profit (PBDIT) of 6.74 Cr, up from 2.80 Cr. Profit before tax surged to 5.70 Cr from 1.82 Cr, leading to a profit after tax of 4.33 Cr, compared to 1.36 Cr the previous year. The earnings per share (EPS) improved significantly to 6.91 from 2.18, while the operating profit margin increased to 24.64% from 16.36%. The total assets of the company grew to 28.10 Cr from 20.70 Cr, with total liabilities also rising to 28..."
      },
      {
        "title": "When is the next results date for Asston Pharmaceu?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-asston-pharmaceu-3694035",
        "imagepath": "",
        "date": "2025-11-12 23:17:58",
        "description": "Asston Pharmaceu is scheduled to declare its results on 14 November 2025...."
      }
    ],
    "total": 6,
    "sid": "10039662",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/asston-pharmaceuticals-10039662"
  },
  "announcements": [
    {
      "caption": "Closure of Trading Window",
      "datetime": "30-Jan-2026",
      "details": "Closure of Trading Window",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
      "datetime": "29-Jan-2026",
      "details": "Resignation of statutory auditor",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Increasing Of Authorised Capital And Raising Of Funds",
      "datetime": "29-Jan-2026",
      "details": "Asston Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2026 inter alia to consider and approve Increase in Authorised Capital and Raising of Funds",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Is Asston Pharmaceu overvalued or undervalued?

2025-11-27 08:53:32

Valuation Metrics and Financial Performance Asston Pharmaceu’s price-to-earnings (PE) ratio of 22.11 places it in the expensive category relative to its historical valuation grade, which recently changed from fair to expensive as of 26 November 2025. The price-to-book value stands at 2.20, indicating the market values the company at more than twice its net asset value. Its enterprise value to EBIT and EBITDA ratios, at 16.47 and 16.35 respectively, suggest the stock is priced at a premium compared to the earnings before interest and taxes and depreciation. The company’s return on capital employed (ROCE) is 12.72%, while return on equity (ROE) is 9.97%. These figures demonstrate moderate efficiency in generating returns from capital and equity, but they do not markedly ...

Is Asston Pharmaceu overvalued or undervalued?

2025-11-18 08:30:42

As of 17 November 2025, the valuation grade for Asston Pharmaceu has moved from very expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE Ratio of 18.10, an EV to EBIT of 13.61, and a ROCE of 12.72%. In comparison to its peers, Asston Pharmaceu's PE Ratio is significantly lower than that of Sun Pharma, which stands at 36.69, and Divi's Lab, which has a PE of 69.78, both of which are categorized as expensive. Conversely, it is on par with Aurobindo Pharma, which is also considered fair with a PE of 21.23. Notably, Asston Pharmaceu has outperformed the Sensex over the past week, returning 6.16% compared to the Sensex's 1.69%....

How has been the historical performance of Asston Pharmaceu?

2025-11-15 00:39:57

Answer: The historical performance of Asston Pharmaceu shows significant growth in various financial metrics from March 2024 to March 2025. Breakdown: Asston Pharmaceu reported net sales of 25.04 Cr in March 2025, a notable increase from 15.59 Cr in March 2024. Total operating income also rose to 25.04 Cr from 15.59 Cr, driven by an increase in raw material costs to 14.13 Cr from 9.75 Cr. The total expenditure, excluding depreciation, increased to 18.87 Cr from 13.04 Cr, resulting in an operating profit (PBDIT) of 6.74 Cr, up from 2.80 Cr. Profit before tax surged to 5.70 Cr from 1.82 Cr, leading to a profit after tax of 4.33 Cr, compared to 1.36 Cr the previous year. The earnings per share (EPS) improved significantly to 6.91 from 2.18, while the operating profit margin increased to 24.64% from 16.36%. The total assets of the company grew to 28.10 Cr from 20.70 Cr, with total liabilities also rising to 28...

When is the next results date for Asston Pharmaceu?

2025-11-12 23:17:58

Asston Pharmaceu is scheduled to declare its results on 14 November 2025....

View All News